Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

HeartWare Drops Valtech Deal Under Shareholder Pressure; Stays Focused On VADs

This article was originally published in The Gray Sheet

Executive Summary

The ventricular-assist device company HeartWare International announced it was terminating its September 2015 agreement to buy heart-valve repair firm Valtech on the same day it disclosed an agreement with an activist shareholder group that opposed the deal.

You may also be interested in...



More Than Just A VAD Maker: HeartWare Broadens Heart Failure Focus With Valtech Buy

The deal will make HeartWare more of a go-to firm for heart-failure specialists, executives say. It comes soon after St. Jude Medical announced its acquisition of Thoratec, another VAD-focused firm whose technology will now be sold alongside a broader set of tools for heart-failure caregivers.

Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent

South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.

CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus

Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.

Topics

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel